valproic acid has been researched along with Alzheimer Disease in 54 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder." | 7.72 | Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. ( Brune, K; Fox, N; Li, B; Liu, F; Ni, B; Paul, S; Ryder, J; Solenberg, P; Su, Y; Wu, X; Zhou, Y, 2004) |
| "We evaluated the effect of the divalproex sodium formulation of valproic acid on brain volumes using MRI in people with mild to moderate Alzheimer disease (AD) and assessed for changes associated with behavioral and cognitive effects." | 5.15 | Chronic divalproex sodium use and brain atrophy in Alzheimer disease. ( Aisen, PS; Cummings, JL; Fleisher, AS; Jack, CR; Langbaum, JB; Mai, JT; Schneider, LS; Tariot, PN; Thomas, RG; Truran, D; Weiner, MW, 2011) |
| " Examining antiepileptic prescribing to residents with ADRD who had disruptive behaviors and/or reported pain suggests that two of the most common antiepileptics, valproic acid and gabapentin, are being used in clinically distinct ways." | 4.31 | Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications. ( Candon, M; Gerlach, LB; Maust, DT; Strominger, J, 2023) |
| " As we have recently shown, inhibitors of histone deacetylases, in particular, valproic acid (VA), were capable of up-regulating NEP expression and activity in human neuroblastoma SH-SY5Y cell lines characterised by very low levels of NEP." | 3.78 | Effect of sodium valproate administration on brain neprilysin expression and memory in rats. ( Bagrova, DI; Belyaev, ND; Dubrovskaya, NM; Lewis, DI; Makova, NZ; Nalivaeva, NN; Pickles, AR; Plesneva, SA; Turner, AJ; Zhuravin, IA, 2012) |
| " Dosing was individualized according to the response of target symptoms and side effects." | 3.78 | An open trial of valproate for agitation in geriatric neuropsychiatric disorders. ( Erb, R; Gaile, S; Porsteinsson, AP; Tariot, PN, 1997) |
| "Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder." | 3.72 | Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. ( Brune, K; Fox, N; Li, B; Liu, F; Ni, B; Paul, S; Ryder, J; Solenberg, P; Su, Y; Wu, X; Zhou, Y, 2004) |
| "Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity." | 2.76 | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. ( Aisen, PS; Bartocci, B; Cummings, J; Fleisher, A; Ismail, MS; Jack, CR; Jakimovich, LJ; Loy, R; Porsteinsson, A; Raman, R; Schneider, LS; Tariot, PN; Thal, L; Thomas, RG; Weiner, M, 2011) |
| "Using Alzheimer's disease and Huntington's disease as examples in the following article, some of latest data linking both the histone code and the various proteins that regulate this code to the pathogenesis of neurological disease are discussed." | 2.47 | Epigenetic treatment of neurological disease. ( Gray, SG, 2011) |
| "Quetiapine combined with sodium valproate is an effective and more suitable drug treatment for Alzheimer's disease." | 1.72 | Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation. ( Fu, K; He, X; Liu, W; Xu, J; Xu, P; Zhang, Z, 2022) |
| "Periorbital edema is a rare side effect of valproate." | 1.62 | Valproate-induced Periorbital Edema. ( Elhamamsy, S; Hatahet, S; Khalaf, K, 2021) |
| "Furthermore, Aβ42, implicated in Alzheimer's disease, undergoes β-sheet to α-helix transition in presence of PIMT." | 1.56 | The role of isoaspartate in fibrillation and its prevention by Protein-L-isoaspartyl methyltransferase. ( Chakrabarti, P; Chatterjee, BK; Chatterjee, T; Das, G; Dhar, J; Ghosh, S, 2020) |
| "Sporadic Alzheimer's disease (SAD) is a slowly progressive neurological disorder that is the most common form of dementia." | 1.46 | Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system. ( El Sayed, NSED; Sorial, ME, 2017) |
| "Valproic acid (VPA) has been shown to have anti-inflammatory function." | 1.42 | Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer's disease. ( Chen, WL; Hong, LP; Ji, WD; Liu, JH; Long, DH; Pan, XB; Wei, P; Xuan, AG; Zhang, WJ, 2015) |
| "Patients with Alzheimer's disease are at increased risk for unprovoked seizures and epilepsy compared with age-matched controls." | 1.42 | Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation. ( Hiltunen, M; Pitkänen, A; Tanila, H; Viswanathan, J; Ziyatdinova, S, 2015) |
| "Valproic acid (VPA) is a widely used mood stabilizer and antiepileptic drug." | 1.39 | Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer's disease mice model. ( Chu, Y; He, G; Long, Z; Song, C; Song, W; Xie, P; Zhao, L; Zheng, M, 2013) |
| "More than 50 % of Alzheimer's disease (AD) patients also exhibit abundant accumulation of α-synuclein (α-Syn)-positive Lewy bodies." | 1.39 | Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease. ( Ferreiro, E; Marques, SC; Oliveira, CR; Pereira, CM; Resende, R; Simões, I, 2013) |
| "Cyproterone acetate was used in a small number of patients at each of the three units." | 1.37 | Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units. ( Lemon, V; Restifo, S; Waters, F, 2011) |
| " Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity." | 1.33 | Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005) |
| "A diagnosis of Alzheimer's disease was made." | 1.29 | [Case report of sodium valproate treatment of aggression associated with Alzheimer's disease]. ( Akagi, M; Takahashi, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (11.11) | 18.2507 |
| 2000's | 16 (29.63) | 29.6817 |
| 2010's | 25 (46.30) | 24.3611 |
| 2020's | 7 (12.96) | 2.80 |
| Authors | Studies |
|---|---|
| Hatahet, S | 1 |
| Khalaf, K | 1 |
| Elhamamsy, S | 1 |
| Zhang, Z | 2 |
| Xu, J | 1 |
| Xu, P | 1 |
| Liu, W | 1 |
| He, X | 1 |
| Fu, K | 1 |
| Zhang, C | 1 |
| Sun, L | 1 |
| Sun, H | 1 |
| Candon, M | 1 |
| Strominger, J | 1 |
| Gerlach, LB | 1 |
| Maust, DT | 1 |
| Ito, Y | 1 |
| Takeda, S | 1 |
| Moroi, S | 1 |
| Nakajima, T | 1 |
| Oyama, A | 1 |
| Miki, K | 1 |
| Sugihara, N | 1 |
| Takami, Y | 1 |
| Takeya, Y | 1 |
| Shimamura, M | 1 |
| Rakugi, H | 1 |
| Morishita, R | 1 |
| Chatterjee, T | 1 |
| Das, G | 1 |
| Chatterjee, BK | 1 |
| Dhar, J | 1 |
| Ghosh, S | 1 |
| Chakrabarti, P | 1 |
| von Mandach, U | 1 |
| Hösli, I | 1 |
| Ruthirakuhan, MT | 1 |
| Herrmann, N | 2 |
| Abraham, EH | 1 |
| Chan, S | 1 |
| Lanctôt, KL | 2 |
| Noh, H | 1 |
| Seo, H | 1 |
| Xuan, AG | 1 |
| Pan, XB | 1 |
| Wei, P | 1 |
| Ji, WD | 1 |
| Zhang, WJ | 1 |
| Liu, JH | 1 |
| Hong, LP | 1 |
| Chen, WL | 1 |
| Long, DH | 1 |
| Bahna, SG | 1 |
| Sathiyapalan, A | 1 |
| Foster, JA | 1 |
| Niles, LP | 1 |
| Yao, ZG | 2 |
| Liang, L | 1 |
| Liu, Y | 1 |
| Zhang, L | 1 |
| Zhu, H | 1 |
| Huang, L | 1 |
| Qin, C | 1 |
| Aller-Alvarez, JS | 1 |
| Menéndez-González, M | 1 |
| Ribacoba-Montero, R | 1 |
| Salvado, M | 1 |
| Vega, V | 1 |
| Suárez-Moro, R | 1 |
| Sueiras, M | 1 |
| Toledo, M | 1 |
| Salas-Puig, J | 1 |
| Álvarez-Sabin, J | 1 |
| Ziyatdinova, S | 1 |
| Viswanathan, J | 1 |
| Hiltunen, M | 1 |
| Tanila, H | 1 |
| Pitkänen, A | 1 |
| Williams, RS | 1 |
| Bate, C | 1 |
| Long, ZM | 1 |
| Zhao, L | 2 |
| Jiang, R | 1 |
| Wang, KJ | 1 |
| Luo, SF | 1 |
| Zheng, M | 2 |
| Li, XF | 1 |
| He, GQ | 1 |
| Jing, HY | 1 |
| Wang, DM | 1 |
| Lv, BB | 1 |
| Li, JM | 1 |
| Liu, FF | 1 |
| Fan, H | 1 |
| Sun, XC | 1 |
| Qin, YJ | 1 |
| Zhao, MQ | 1 |
| Long, Z | 2 |
| Zeng, Q | 1 |
| Wang, K | 2 |
| Sharma, A | 1 |
| He, G | 3 |
| Sorial, ME | 1 |
| El Sayed, NSED | 1 |
| Qing, H | 1 |
| Ly, PT | 1 |
| Fox, CJ | 1 |
| Staufenbiel, M | 1 |
| Cai, F | 1 |
| Wei, S | 1 |
| Sun, X | 1 |
| Chen, CH | 1 |
| Zhou, W | 1 |
| Song, W | 2 |
| Tariot, PN | 10 |
| Aisen, PS | 3 |
| España, J | 1 |
| Giménez-Llort, L | 1 |
| Valero, J | 1 |
| Miñano, A | 1 |
| Rábano, A | 1 |
| Rodriguez-Alvarez, J | 1 |
| LaFerla, FM | 1 |
| Saura, CA | 1 |
| Zhang, XZ | 1 |
| Li, XJ | 1 |
| Zhang, HY | 1 |
| Dolder, C | 1 |
| McKinsey, J | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Nuutinen, T | 1 |
| Suuronen, T | 1 |
| Kauppinen, A | 1 |
| Salminen, A | 1 |
| Xiao, H | 1 |
| Su, Y | 2 |
| Cao, X | 1 |
| Sun, S | 1 |
| Liang, Z | 1 |
| Restifo, S | 1 |
| Lemon, V | 1 |
| Waters, F | 1 |
| Schneider, LS | 2 |
| Cummings, J | 1 |
| Thomas, RG | 2 |
| Raman, R | 2 |
| Jakimovich, LJ | 1 |
| Loy, R | 4 |
| Bartocci, B | 1 |
| Fleisher, A | 1 |
| Ismail, MS | 1 |
| Porsteinsson, A | 4 |
| Weiner, M | 1 |
| Jack, CR | 2 |
| Thal, L | 2 |
| Fleisher, AS | 1 |
| Truran, D | 1 |
| Mai, JT | 1 |
| Langbaum, JB | 1 |
| Cummings, JL | 1 |
| Weiner, MW | 1 |
| Nalivaeva, NN | 1 |
| Belyaev, ND | 1 |
| Lewis, DI | 1 |
| Pickles, AR | 1 |
| Makova, NZ | 1 |
| Bagrova, DI | 1 |
| Dubrovskaya, NM | 1 |
| Plesneva, SA | 1 |
| Zhuravin, IA | 1 |
| Turner, AJ | 1 |
| Gray, SG | 1 |
| Xie, P | 1 |
| Song, C | 1 |
| Chu, Y | 1 |
| Resende, R | 1 |
| Marques, SC | 1 |
| Ferreiro, E | 1 |
| Simões, I | 1 |
| Oliveira, CR | 1 |
| Pereira, CM | 1 |
| Ryan, JM | 1 |
| Ismail, S | 1 |
| Vance, H | 1 |
| Kauffman, C | 1 |
| Miller, B | 1 |
| Mansour, T | 1 |
| Ryder, J | 1 |
| Li, B | 1 |
| Wu, X | 1 |
| Fox, N | 1 |
| Solenberg, P | 1 |
| Brune, K | 1 |
| Paul, S | 1 |
| Zhou, Y | 1 |
| Liu, F | 1 |
| Ni, B | 1 |
| Rosin, RA | 1 |
| Raskind, MA | 2 |
| Jakimovich, L | 2 |
| Schneider, L | 1 |
| Thomas, R | 1 |
| Mintzer, J | 1 |
| Brenner, R | 1 |
| Schafer, K | 1 |
| Profenno, LA | 2 |
| Holt, CJ | 1 |
| Rothenburg, LS | 1 |
| Eryavec, G | 1 |
| Mhyre, TR | 1 |
| Maguire-Zeiss, KA | 1 |
| Zhang, D | 1 |
| Coleman, PD | 1 |
| Federoff, HJ | 1 |
| Borhani Haghighi, A | 1 |
| Sabayan, B | 1 |
| Wang, XC | 1 |
| Zhang, YC | 1 |
| Chatterjie, N | 1 |
| Grundke-Iqbal, I | 1 |
| Iqbal, K | 1 |
| Wang, JZ | 1 |
| Auchus, AP | 1 |
| Freeman, A | 1 |
| Green, RC | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Takahashi, M | 1 |
| Akagi, M | 1 |
| Porsteinsson, AP | 1 |
| Erb, R | 1 |
| Gaile, S | 1 |
| Narayan, M | 1 |
| Nelson, JC | 1 |
| Regenold, WT | 1 |
| Prasad, M | 1 |
| Iijima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)[NCT00071721] | Phase 3 | 313 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia[NCT00375557] | Phase 4 | 0 participants (Actual) | Interventional | 2006-10-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver rating questionnaire for the assessment of agitation in older persons. It includes descriptions of 29 agitated behaviors, each rated on a 7-point scale of frequency. The range of this instrument is 29 to 203 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 10.6 |
| Placebo | 12.1 |
Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year (ADAS-cog) is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 42.3 |
| Placebo | 41.9 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Score (ADCS-ADL) is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 35.1 |
| Placebo | 41.0 |
Clinical Dementia Rating, Sum of Boxes (CDR-SOB) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 12.0 |
| Placebo | 11.5 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) provides a means to reliably assess global change from baseline. It provides a semi-structured format to allow clinicians to gather necessary clinical information from both the participant and informant, in order to make an overall impression of clinical change. The range of this instrument is 1 to 7 with lower numbers indicating improvement and higher numbers indicating a worsened state. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 5.7 |
| Placebo | 5.5 |
NPI quantifies behavioral changes in dementia, including depression, anxiety, psychosis, agitation, and others. This is a questionnaire administered to the subject's study partner. The range of this instrument is 0 to 120 with higher numbers indicating greater impairment. To determine whether or not psychosis or agitation is present, there is no cutoff score but is based on the clinician's judgment. In the NPI, the subject responds to 'Yes' or 'No' questions. Then it is determined how often psychosis or agitation occurs and if it is mild, moderate or severe. (NCT00071721)
Timeframe: 24 months
| Intervention | Participants (Number) |
|---|---|
| Valproate | 25 |
| Placebo | 29 |
9 reviews available for valproic acid and Alzheimer Disease
| Article | Year |
|---|---|
Effects of magnesium valproate adjuvant therapy on patients with dementia: A systematic review and meta-analysis.
Topics: Activities of Daily Living; Alzheimer Disease; Cognition; Humans; Mental Status and Dementia Tests; | 2022 |
Pharmacological interventions for apathy in Alzheimer's disease.
Topics: Alanine; Alzheimer Disease; Antidepressive Agents; Apathy; Azepines; Benzhydryl Compounds; Biphenyl | 2018 |
Valproic acid as a promising agent to combat Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Humans; Models, Neurological; Neurogenesis; Neurons; Neuroprotective Age | 2010 |
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
A meta-analysis of mood stabilizers for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antimanic Agents; Carbamazepine; Female; Humans; Lithium; Male; Middle Aged | 2010 |
Epigenetic treatment of neurological disease.
Topics: Alzheimer Disease; Butylamines; Cell Differentiation; Endoplasmic Reticulum Stress; Epigenesis, Gene | 2011 |
Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Mood Disorders; Neuroprotective Agents | 2002 |
An open trial of valproate for agitation in geriatric neuropsychiatric disorders.
Topics: Aged; Alzheimer Disease; Female; GABA Agents; Humans; Male; Mental Disorders; Valproic Acid | 1997 |
Evaluation and management of aggressive behavior in the elderly demented patient.
Topics: Age Factors; Aged; Aggression; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Cholinergic | 1999 |
8 trials available for valproic acid and Alzheimer Disease
| Article | Year |
|---|---|
Low-dose divalproex in agitated patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antimanic Agents; Female; Humans; Male; Psychomotor Agit | 2010 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Ag | 2011 |
Chronic divalproex sodium use and brain atrophy in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Atrophy; Brain; Double-Blind Metho | 2011 |
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; D | 2005 |
A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Double-Blind Method; Humans; Neuroprote | 2005 |
A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Cognition Disorders; Double | 2007 |
Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cells, Cultured; Humans; Leukocytes; Mi | 2008 |
An open trial of valproate for agitation in geriatric neuropsychiatric disorders.
Topics: Aged; Alzheimer Disease; Female; GABA Agents; Humans; Male; Mental Disorders; Valproic Acid | 1997 |
38 other studies available for valproic acid and Alzheimer Disease
| Article | Year |
|---|---|
Valproate-induced Periorbital Edema.
Topics: Aged; Aggression; Alzheimer Disease; Edema; Humans; Male; Valproic Acid | 2021 |
Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation.
Topics: Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Dibenzothiazepines; Humans; Neurodegen | 2022 |
Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications.
Topics: Aged; Alzheimer Disease; Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Gabapentin; Huma | 2023 |
Antiepileptic Drugs Modulate Alzheimer-Related Tau Aggregation in a Neuronal Activity-Independent Manner.
Topics: Aged; Alzheimer Disease; Anticonvulsants; Humans; Phenobarbital; tau Proteins; Valproic Acid | 2023 |
The role of isoaspartate in fibrillation and its prevention by Protein-L-isoaspartyl methyltransferase.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Anticonvulsants; Aspartic Acid; Benzothi | 2020 |
Valproate in pregnancy: comment from the SAPP.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Female; Humans; Pregnancy; Valproic Acid | 2021 |
Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation.
Topics: Aging; Alzheimer Disease; Animals; Blotting, Western; Disease Models, Animal; Enzyme Inhibitors; Hip | 2014 |
Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Death; Cytokines; Histone | 2015 |
Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; CA1 Region, Hippocampal; CA2 Region, Hippocampal; CA3 Region, Hippocampa | 2014 |
Valproate improves memory deficits in an Alzheimer's disease mouse model: investigation of possible mechanisms of action.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Memory; Memory D | 2014 |
Myoclonic epilepsy in Down syndrome and Alzheimer disease.
Topics: Adult; Aged; Alzheimer Disease; Anticonvulsants; Down Syndrome; Electroencephalography; Epilepsies, | 2017 |
Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti | 2015 |
An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Cholesterol; Dose-Response Relat | 2016 |
Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cells, Cultured; Enzyme Inhibitor | 2015 |
Valproic acid ameliorates olfactory dysfunction in APP/PS1 transgenic mice of Alzheimer's disease: Ameliorations from the olfactory epithelium to the olfactory bulb.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Mice; Olfactory Bulb; Olfactory Mucosa; | 2016 |
Gender difference in valproic acid-induced neuroprotective effects on APP/PS1 double transgenic mice modeling Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticonvulsants; | 2016 |
Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Diseas | 2017 |
Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2008 |
Can lithium or valproate untie tangles in Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Anticonvulsants; Brain; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Huma | 2009 |
Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Amyloid beta-Peptides; Amyloid beta-Protein Pr | 2010 |
Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease.
Topics: Alzheimer Disease; Astrocytes; Cells, Cultured; Clusterin; Histone Deacetylase Inhibitors; Humans; V | 2010 |
Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units.
Topics: Aged; Alzheimer Disease; Androgen Antagonists; Antipsychotic Agents; Cholinesterase Inhibitors; Cypr | 2011 |
Effect of sodium valproate administration on brain neprilysin expression and memory in rats.
Topics: Alzheimer Disease; Animals; Anticonvulsants; Cell Line, Tumor; Disease Models, Animal; Female; Human | 2012 |
Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer's disease mice model.
Topics: Alzheimer Disease; Animals; Apoptosis; Blotting, Western; Brain; Disease Models, Animal; Female; Flo | 2013 |
Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cerebral Cortex; Neur | 2013 |
Neuroprotective properties of valproate: potential benefit for AD and tauopathies.
Topics: Alzheimer Disease; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclic AMP Response Element-B | 2002 |
Treatment of agitation using Depakote: a patient with dementia.
Topics: Affect; Aggression; Alzheimer Disease; Anxiety; Cooperative Behavior; Dose-Response Relationship, Dr | 2003 |
Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Bipolar Disorder; Brain; Cells, Cultured | 2004 |
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo | 2005 |
Clinical trials of amyloid-based therapies for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antibodies, Monoclonal; Brain; Humans; Hydroxymet | 2007 |
Can prolonged administration of valproic acid put patients with epilepsy at higher risk for development of Alzheimer's disease?
Topics: Alzheimer Disease; Anticonvulsants; Epilepsy; Humans; Valproic Acid | 2008 |
Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Melatonin; Mice; Neuroblastoma; | 2008 |
Agitated behavior relieved following treatment of cervical dystonia in dementia.
Topics: Alzheimer Disease; Botulinum Toxins; Chlorpromazine; Dystonia; Female; Humans; Isoxazoles; Middle Ag | 1995 |
Treating the agitated Alzheimer patient.
Topics: Adrenergic beta-Antagonists; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Buspirone; C | 1996 |
[Case report of sodium valproate treatment of aggression associated with Alzheimer's disease].
Topics: Aged; Aggression; Alzheimer Disease; Anticonvulsants; Humans; Male; Valproic Acid | 1996 |
Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Administration Sche | 1997 |
Uses of intravenous valproate in geriatric psychiatry.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Female; Geriatric Ps | 2001 |
Valproate-induced parkinsonism in a demented elderly patient.
Topics: Aged; Aggression; Alzheimer Disease; Humans; Male; Parkinsonian Disorders; Valproic Acid; Violence | 2002 |